Control and lot release of meningococcal group C conjugate vaccines

Expert Review of Vaccines

Volumn 3, Issue 5, 2004, Pages 533-540

  Suker, Janet ^a   Feavers, Ian M ^a   Corbel, Michael J ^a   Jones, Christopher ^a   Bolgiano, Barbara ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Control; For release; High performance anion exchange chromatography with pulsed amperometric detection; Meningococcal group C conjugate vaccine; Nuclear magnetic resonance spectroscopy; Size exclusion chromatography

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; CARRIER PROTEIN; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; NEISVAC C; POLYSACCHARIDE;

ANTIGENIC VARIATION; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONJUGATE; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFECTION CONTROL; INTERNATIONAL COOPERATION; MEDICAL EXPERT; META ANALYSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNITED KINGDOM; VACCINE PRODUCTION;

ALUMINUM COMPOUNDS; ANIMALS; DRUG STABILITY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; POLYSACCHARIDES, BACTERIAL; QUALITY CONTROL; VACCINES, CONJUGATE;

EID: 7444221240     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.5.533     Document Type: Review

References (60)

1. Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin. Microbiol. Rev. 2, S118-S124 (1989).
2. Bethell D, Pollard AJ. Meningococcal vaccines. Expert Rev. Vaccines 1(1), 75-84 (2002).
3. Riddell A, Buttery J. Vaccines against meningococcal disease: current and future technologies. Expert Opin. Biol. Ther. 1(3), 385-399 (2001).
4. Granoff DM, Feavers IM, Borrow R. Meningococcal Vaccines. In: Vaccines. Plotkin SA, Orenstein WA (Eds). Saunders, PA, USA, 959-987 (2004).
5. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129, 1307-1326 (1969).
6. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129, 1327-1348 (1969).
7. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 60, 673-680 (1977).
8. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotshlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. 140(5), 690-697 (1979).
9. Gold R, Lepow ML, Goldschneider I, Gotschlich EC. Immune response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J. Infect. Dis. 136(Suppl.), S31-S35 (1977).
10. Rubinstein LJ, Stein KE. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny. J. Immunol. 141, 4352-4356 (1988).
11. Goldblatt D. Immunization and the maturation of infant immune responses. Dev. Biol. Stand. 95, 125-132 (1998).
12. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165(Suppl. 1), S49-S52 (1992).
13. Goldblatt D, Borrow R, Miller E. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J. Infect. Dis. 185(3), 397-400 (2002).
14. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr. Infect. Dis. J. 17(Suppl. 9), S117-S122 (1998).
15. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 340, 592-594 (1992).
16. Caugant DA, Froholm LO, Bovre K. et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl Acad. Sci. USA 83, 4927-4931 (1986).
17. Caugant DA, Bovre K, Gaustad P et al. Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. J. Gen. Microbiol. 132, 641-652 (1986).
18. Wang J-F, Caugant DA, Morelli G, Koumaré B, Achtman M. Antigenic and epidemiological properties of the ET-37 complex of Neisseria meningitidis. J. Infect. Dis. 167, 1320-1329 (1993).
19. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl. 1), S58-S67 (2001).
20. Balmer P, Borrow R. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev. Vaccines 3(1), 77-87 (2004).
21. Jodar L, Cartwright K, Feavers IM. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biolagicals 28(3), 193-197 (2000).
22. Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 16(14-15), 1391-1395 (1998).
23. Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal c polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J. Infect. Dis. 184(3), 377-380 (2001).
24. Richmond P, Borrow R, Goldblatt D et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183(1), 160-163 (2001).
25. Richmond P, Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Inject. Dis. 181(2), 761-764 (2000).
26. Choo S, Zuckerman J, Goilav C et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomized observer-blind controlled trial. Vaccine 18(24), 2686-2692 (2000).
27. English M, MacLennan JM, Bowen-Morris JM et al. A randomized, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 19(9-10), 1232-1238 (2000).
28. MacLennan JM, Shackley F, Heath PT et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 283(21), 2795-2801 (2000).
29. Bramley JC, Hall T, Finn A et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 19(20-22), 2924-2931 (2001).
30. Borrow R, Southern J, Andrews N et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 19(23-24), 3043-3050 (2001).
31. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51(9), 717-722 (2002).
32. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. J. 326(7385), 365-366 (2003).
33. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359(9320), 1829-1831 (2002).
34. Griffiths E, Knezevic I. Assuring the quality and safety of vaccines: regulatory licensing and batch release. Methods Mol. Med. 87, 353-376 (2003). Describes issues for regulation and quality control of vaccines in general.
35. Milstien J, Dellepiane N, Lambert S et al. Vaccine quality - can a single standard be defined? Vaccine 20(7-8), 1000-1003 (2002). Describes issues for regulation and quality control of vaccines in general.
36. Recommendations for the production and control of Hib conjugate vaccines. WHO Technical Report Series 897, 27-56 (2000).
37. Jones C, Crane DT, Lemercinier X, Bolgiano B, Yost SE. Physicochemical studies of the structure and stability of polysaccharide-protein conjugate vaccines. Dev. Biol. Stand. 87, 143-151 (1996).
38. Tsai CM, Gu XX, Byrd RA. Quantification of polysaccharide in Haemophilus influenzae type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection. Vaccine 12(8), 700-706 (1994).
39. Jumel K, Ho MM, Bolgiano B. Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography/multi-angle laser light scattering. Biotechnol. Appl. Biochem. 36(3), 219-226 (2002).
40. 197 conjugate vaccines. Vaccine 19(7-8), 716-725 (2000). Describes useful methods for the control testing of MenC vaccines and illustrates the correlation between physicochemical and immunogenicity data.
41. 197 conjugate vaccines. Dev. Biol. (Basel) 103, 93-104 (2000). Describes useful approaches for testing MenC and pneumococcal conjugates.
42. Lei QP, Shannon AG, Heller RK, Lamb DH. Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines. Dev. Biol. (Basel) 103, 259-264 (2000).
43. Richmond P, Borrow R, Findlow J et al. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acerylated and De-O-acetylated serogroup C strains. Infect. Immun. 69(4), 2378-2382 (2001).
44. Glode MP, Lewin EB, Sutton A et al. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J. Infect. Dis. 139, 52-59 (1979).
45. Lemercinier X, Jones C. Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr. Res. 296, 83-96 (1996).
46. Jones C, Lemercinier X. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J. Pharma. Biomed. Anal. 30, 1233-1247 (2002).
47. Jones C, Lemercinier X, Crane DT, Gee CK, Austin S. Spectroscopic studies of the structure and stability of glycoconjugate vaccines. Dev. Biol. (Basel) 103, 121-136 (2000).
48. 197 conjugate vaccines. Vaccine 19(23-24), 3189-3200 (2001).
49. Ho MM, Lemercinier X, Bolgiano B, Corbel MJ. Monitoring stability of meningococcal group C conjugate vaccines; correlation of physicochemical methods and immunogenicity assays. Dev. Biol. (Basel) 103, 139-150 (2000).
50. Ho MM, Mawas F, Bolgiano B et al. Physicochemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine 20(29-30), 3509-3522 (2002).
51. Hendriksen CF. Refinement, reduction, and replacement of animal use for regulatory testing: current best scientific practices for the evaluation of safety and potency of biologicals. ILAR. J. 43(Suppl), S43-S48 (2002).
52. Jodar L, Griffiths E, Feavers I. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine 22, 1047-1053 (2004). Describes in detail the current World Health Organization (WHO) recommendations for control and lot release of MenC conjugate vaccines.
53. Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175, 200-204 (1997).
54. Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361 (9372), 1902-1904 (2003).
55. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Pediatr. Child Health 37(5), S20-S27 (2001).
56. Kellerman SE, McCombs K, Ray M et al. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J. Infect. Dis. 186(1), 40-48 (2002).
57. Mayer LW, Reeves MW, Al Hamdan N et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J. Infect. Dis. 185(11), 1596-1605 (2002).
58. Issa M, Molling P, Unemo M et al. Neisseria meningitidis serogroup W-135 isolated from healthy carriers and patients in Sudan after the Hajj in 2000. Scand. J. Infect. Dis. 35(4), 230-233 (2003).
59. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 (9368), 1521-1523 (2003).
60. Granoff DM. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin. Infect. Dis. 33(SuppL 4), S278-S287 (2001).